Compare · BFRG vs NVO
BFRG vs NVO
Side-by-side comparison of Bullfrog AI Holdings Inc. (BFRG) and Novo Nordisk A/S (NVO): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both BFRG and NVO operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- NVO is the larger of the two at $168.79B, about 17102.1x BFRG ($9.9M).
- Over the past year, BFRG is down 62.6% and NVO is down 30.3% - NVO leads by 32.3 points.
- Both names hit the wire about 4 times in the past 4 weeks.
- NVO has more recent analyst coverage (25 ratings vs 0 for BFRG).
- Company
- Bullfrog AI Holdings Inc.
- Novo Nordisk A/S
- Price
- $0.55-0.67%
- $39.08-0.40%
- Market cap
- $9.9M
- $168.79B
- 1M return
- +18.86%
- -9.55%
- 1Y return
- -62.58%
- -30.32%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ
- NYSE
- IPO
- 2023
- News (4w)
- 4
- 4
- Recent ratings
- 0
- 25
Novo Nordisk A/S
Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases. The Biopharmaceuticals segment offers products in the areas of haemophilia, growth disorders, and hormone replacement therapy. The company collaboration agreements with Lund University to develop treatment for Parkinson's diseases; and bluebird bio, Inc. to develop genome editing treatments for children and adult patients. Novo Nordisk A/S also has a research collaboration with Lumen Bioscience, Inc. to explore strategies for delivering oral biologics for cardiometabolic disease. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
Latest BFRG
- BullFrog AI to Present at the 20th Annual LD Micro Main Event on October 20, 2026
- BullFrog AI Announces Positive Progress in Drug Discovery Program for Top 5 Global Pharmaceutical in Major Depressive Disorder
- Chief Financial Officer Blacher Joshua bought $26,425 worth of shares (50,000 units at $0.53), increasing direct ownership by 333% to 65,000 units (SEC Form 4)
- Chief Executive Officer Singh Vininder bought $44,918 worth of shares (75,000 units at $0.60), increasing direct ownership by 3% to 2,442,446 units (SEC Form 4)
- BullFrog AI to Participate in September 2026 Investor Conferences
- iAccess Alpha Virtual Best Ideas Fall Investment Conference, September 15-16, 2026
- Bullfrog AI Holdings Inc. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
- BullFrog AI to Participate in the BTIG Virtual Biotechnology Conference
- BullFrog AI to Participate in Water Tower Research Fireside Chat on Thursday, July 23, 2026
- SEC Form 424B3 filed by Bullfrog AI Holdings Inc.
Latest NVO
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- Novo Nordisk A/S downgraded by Morgan Stanley with a new price target
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- Novo Nordisk A/S downgraded by Deutsche Bank